You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Tucson, Arizona-based company previously raised $20 million through a public offering of its shares and a purchase deal with certain investors.
The investment bank, which maintained its $60 price target for the company's stock, said it is looking for signs of revenue acceleration.
The investment bank initiated coverage on Rosetta Genomics and Veracyte, rating the molecular diagnostic firms' shares speculative buy and buy, respectively.
The company also said that its cash burn rate for Q2 is estimated to be about $4.8 million, or $1.3 million more than its average cash burn.
Cantor will offer PacBio's stock in an "at-the-market" offering, though the investment bank may also sell the shares through other methods.
Science reports that a new White House Office of Management and Budget memo rescinds previous ones that helped research institutions deal with pandemic-related closures.
Researchers report on a concerning strain of the H1N1 swine flu virus found among pigs in China, Agence France Presse reports.
The Associated Press reports that US officials are considering allowing pooled COVID-19 testing.
In Genome Research this week: Y chromosome gene expression analysis, de novo mutations rise with paternal age in rhesus macaques, and more.